- Anticonvulsants
- Antidepressants
- Antidopaminergics
- Antipsychotics
- Others
Huntington’s Disease Treatment Market report gives a comprehensive outlook on across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on global Huntington’s Disease Treatment market gives historical, current, and future market sizes (US$ Mn) of drug class, route of administration, distribution channel and geographic regions. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of global market. Huntington’s disease is an inherited disorder caused due to degeneration of the nerve cells in the brain. Huntington’s disease signs and symptoms appear in people with 30 to 40 years of age and sometimes disease causes in below 20 years of age group. Most common symptoms of Huntington's disease include difficulties in learning, lack of flexibility, muscle problems, abnormalities in speech, and lack of impulse control. Moreover, depression is the most common psychiatric disorder occurs with Huntington's disease and caused due to damage of brain cells and changes in brain function. There is no permanent treatment for Huntington's disease however, medications are available to manage the symptoms of Huntington's disease. In April 2017, Teva Pharmaceuticals Industries Ltd. received U.S. FDA approval for Austedo tablets used in the treatment of Huntington's disease treatment. In September 2016, Voyager Therapeutics, Inc. collaborated with CHDI Foundation, Inc. (CHDI) foundation to develop novel gene therapy for the treatment of Huntington's disease.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the prevalence of Huntington’s disease, a rise in R&D activities for the innovation of newer drugs, availability of symptomatic treatment drugs, and rise in the geriatric population is anticipated to fuel the Huntington’s disease treatment market over the forecast period. Moreover, favourable reimbursement policies, a rise in the awareness regarding mental health among key stakeholders, and various pipeline drugs are driving the Huntington’s disease treatment market growth. However, stringent regulatory guidelines and a dearth of treatment options are expected to hinder the growth of Huntington’s Disease Treatment Market
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
[urltag url='request-table-of-content']